SECOND AMENDED AND RESTATED NANO-REFORMULATED COMPOUND LICENSE AGREEMENTLicense Agreement • March 26th, 2020 • Zyla Life Sciences • Pharmaceutical preparations • Delaware
This Second Amended and Restated Nano-Reformulated Compound License Agreement (this “Agreement”), dated January 27, 2020 (the “Effective Date”), is made by and among iCeutica Inc., a Delaware corporation (“iCeutica Inc.”), its wholly-owned subsidiary iCeutica Pty Ltd., an Australian corporation (together, “iCeutica”), and Zyla Life Sciences US Inc., a Delaware corporation (“Zyla”). iCeutica and Zyla are individually referred to herein as a “Party” and collectively referred to herein as the “Parties.”
EMPLOYMENT SEPARATION AGREEMENT AND GENERAL RELEASEEmployment Separation Agreement • March 26th, 2020 • Zyla Life Sciences • Pharmaceutical preparations • Pennsylvania
THIS EMPLOYMENT SEPARATION AGREEMENT AND GENERAL RELEASE (the “Agreement”) is entered into by and between Zyla Life Sciences US Inc., a Delaware Corporation (the “Company”), and H. Jeffrey Wilkins, MD (“Executive” or “Wilkins”), effective following Executive’s signature of it without timely revocation (the “Effective Date”).
